House passes limited medical-cannabis policy; companion cultivation bill fails

The Utah House on Feb. 9 passed a third substitute of House Bill 195, authorizing tightly controlled access to cannabis-based medicines for patients a physician reasonably believes are terminally ill. Representative Doff, who moved the substitute under the name of Representative Dawe, said the change narrows the definition of "terminally ill" and restricts recommendations to physicians only. "It tightens up the definition of what 'terminally ill' means and, also, allows only physicians to do the recommending," Doff said on the floor.

The bill limits the forms that may be dispensed to non-smokeable, medicinal formulations — pills, gels, transdermals or oils — and caps the number of patients per recommending physician at roughly 15–25 in consultation with the Utah Medical Association. Sponsors said the cap prevents physicians from becoming the primary source for these medicines. Representative Dawe added the policy is intended to be a cautious, data-driven step. "We will let science lead the way," Dawe said.

Floor debate touched on several topics: whether the use is authorized under federal law (several members noted it is not), whether advanced practice registered nurses (APRNs) should be permitted to recommend (the substitute restricts recommendations to physicians), and the planned source of supply. Representative Doff and Representative Dawe explained that House Bill 197 — a companion bill — would authorize the Department of Agriculture to grow or contract to grow cannabis in-state, process it into standardized preparations, and make it available for Right-to-Try and research.

Representative concerns included federal preemption and youth exposure, and several members urged caution. A physician-member clarified the hospice definition of "six months" is a physician’s best clinical estimate and not an exact line. "That is a physician's best estimate, and it's not a hard, you know, line in the sand," the physician said.

Later on the floor the House considered HB197 (cannabis cultivation amendments), which would have authorized the Department of Agriculture to contract for in‑state production limited to research and Right-to-Try. Sponsors said an in-state source is needed to avoid interstate transport and to provide consistent, research-grade material. Opponents raised concerns about monopoly, distribution controls, and collecting sales tax on largely cash transactions. After a call of the House the second substitute for HB197 failed on a close vote, recorded as 36 yea and 34 nay; the bill was referred to staff for filing.

The third substitute HB195 passed on the House floor by a vote of 48–26 and will be forwarded to the Senate.